Key result
Ceruloplasmin levels were significantly elevated in ischemic and nonischemic cardiomyopathy patients compared to controls (P<0.001) and independently associated with heart failure severity.
Why the study?
Are elevated ceruloplasmin levels associated with the extent of heart failure in patients with ischemic and nonischemic cardiomyopathy?
Case-Control (n=296)
Are elevated ceruloplasmin levels associated with the extent of heart failure in patients with ischemic and nonischemic cardiomyopathy?
p-value: p=<0.001
Ceruloplasmin is elevated in heart failure patients and serves as an independent biomarker for disease severity in nonischemic cardiomyopathy.
Supports ceruloplasmin as a severity marker in cardiomyopathy; hypothesis-generating and requires prospective validation before clinical use.
OBJECTIVE: Ceruloplasmin was elevated in patients with coronary heart disease, but the relationship between ceruloplasmin and heart failure was still unknown. We aimed to evaluate ceruloplasmin in heart failure patients and assess association between ceruloplasmin and the extent of heart failure. METHODS AND RESULTS: 202 heart failure patients were divided into ischemic (78 with coronary stenosis) and nonischemic groups (124 without coronary stenosis). 94 subjects without heart failure were included as controls. The extent of heart failure was defined according to NYHA classification. Ceruloplasmin levels in ischemic (P < 0.001) and nonischemic groups (P < 0.001) were higher than those in control group. Ceruloplasmin had a positive linear correlation with C-reactive protein (P < 0.01) and a negative linear correlation with LVEF (P < 0.05). In nonischemic group, CP levels were significantly different among different NYHA subgroups (P < 0.05). The correlation between ceruloplasmin and extent of heart failure was calculated by binary logistic regression. Ceruloplasmin showed an independent association with the extent of heart failure in nonischemic cardiomyopathy patients (P < 0.05). CONCLUSIONS: Ceruloplasmin was significantly elevated in patients with ischemic or nonischemic cardiomyopathy and had linear correlation with C-reactive protein and LVEF. In nonischemic cardiomyopathy patients, the ceruloplasmin value was an independent biomarker associated with the extent of heart failure.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2013) conducted a case-control in Heart failure (n=296). Ceruloplasmin vs. Subjects without heart failure was evaluated on Presence and extent of heart failure (NYHA classification) (p=<0.001). Ceruloplasmin levels were significantly elevated in ischemic and nonischemic cardiomyopathy patients compared to controls (P<0.001) and independently associated with heart failure severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: